Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 16/20 | 0.63 |
| ▸ | CBFB | Q13951 | 3/20 | 0.61 |
| ▸ | SCD | O00767 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1656643 | 0.97 | GCK (0.67) | GCKCBFBSCD | |
| SCHEMBL1659191 | 0.92 | GCK (0.75) | GCKCBFB | |
| SCHEMBL1656395 | 0.89 | GCK (0.79) | GCKCBFB | |
| SCHEMBL2297097 | 0.88 | CBFB (0.61) | GCKCBFB | |
| SCHEMBL12730485 | 0.85 | GCK (0.58) | GCKCBFB | |
| SCHEMBL1657642 | 0.85 | GCK (0.62) | GCKCBFBSCD | |
| SCHEMBL2645980 | 0.85 | CBFB (0.62) | GCKCBFBSCD | |
| SCHEMBL1656417 | 0.84 | GCK (0.61) | GCKCBFBSCD | |
| SCHEMBL2644329 | 0.84 | CBFB (0.61) | GCKCBFBSCD | |
| SCHEMBL1657206 | 0.84 | CBFB (0.64) | GCKCBFBSCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1905769-B1 | HETEROCYCLE-SUBSTITUTED BENZIMIDAZOLE DERIVATIVE | MSD KK (JP) | 2017-03-29 | — | — | EP | disclosed |
| US-7994331-B2 | Heterocycle-substituted benzimidazole derivative | MSD K.K. (JP) | 2011-08-09 | — | — | US | disclosed |
| US-20100087360-A1 | Heterocycle-substituted benzimidazole derivative | MSD K.K. (JP) | 2010-04-08 | — | — | US | disclosed |
| EP-1905769-A1 | HETEROCYCLE-SUBSTITUTED BENZIMIDAZOLE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-04-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087360-A1 | Heterocycle-substituted benzimidazole derivative | GCK, GCKR, HK1 | GCK 1/4885CBFB 2061/4885SCD 4077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.